Skip to content
Homepage
Category:
PRNewswire
Posted Date:
June 7, 2026
FSK Investors Have Opportunity to Lead FS KKR Capital Corp. Securities Fraud Lawsuit
THE ROSEN LAW FIRM, P. A.
June 7, 2026
Novo Nordisk’s CagriSema 2.4 mg / 2.4 mg demonstrated significant reduction in HbA1c and weight across multiple studies in the REIMAGINE program presented at ADA 2026
NOVO NORDISK INC.
June 7, 2026
Once-Weekly CagriSema (Amylin-Semaglutide) Combination Injection More Effective than Standalone Medications
AMERICAN DIABETES ASSOCIATION
June 7, 2026
Lipid-Lowering Medications Demonstrate Cardiometabolic Benefits in Populations with High-Risk Diabetes
AMERICAN DIABETES ASSOCIATION
June 7, 2026
AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS
AMGEN
June 7, 2026
Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide
Sciwind Biosciences Co., Ltd.
June 7, 2026
Once-Weekly Drug Demonstrates Promising Dual Benefits in Obesity and Metabolic Health
AMERICAN DIABETES ASSOCIATION
June 7, 2026
Rosen Law Firm Encourages DNOW Inc. Investors to Inquire About Securities Class Action Investigation – DNOW
THE ROSEN LAW FIRM, P. A.
June 7, 2026
Prev
1
…
457
458
459
